Compare CBLL & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBLL | INMD |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.2M | 854.5M |
| IPO Year | 2024 | 2018 |
| Metric | CBLL | INMD |
|---|---|---|
| Price | $24.74 | $14.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $23.20 | $17.33 |
| AVG Volume (30 Days) | 359.7K | ★ 408.3K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,063,000.00 | N/A |
| Revenue This Year | $29.57 | $1.74 |
| Revenue Next Year | $28.44 | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | ★ 36.09 | N/A |
| 52 Week Low | $10.85 | $12.72 |
| 52 Week High | $25.33 | $16.74 |
| Indicator | CBLL | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 72.01 | 47.49 |
| Support Level | $22.97 | $14.94 |
| Resistance Level | $25.33 | $15.25 |
| Average True Range (ATR) | 0.78 | 0.17 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 75.00 | 35.70 |
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.